Pentadecapeptide BPC (BPC, Body Protection Compound)

Cartalax has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. The evidence base consists of cell culture studies published by the originating research group. As with other Khavinson bioregulator peptides, the proposed tissue-targeting mechanisms have not been independently validated. Products available through unregulated channels lack pharmaceutical quality assurance.

TB-500 has no marketing authorisation from any regulatory agency. No human clinical trials of TB-500 specifically have been conducted. The evidence base relies on animal studies of both TB-500 and its parent molecule thymosin beta-4, which are not pharmacologically equivalent. TB-500 is prohibited by WADA and is known from equine and greyhound racing contexts. Products available through unregulated channels lack pharmaceutical quality assurance. The absence of any human safety or efficacy data means that the compound's effects, risks, interactions, and appropriate dosing in humans are unknown.

BPC-157 has no marketing authorisation from any major regulatory agency. No human Phase III clinical trials have been completed. The preclinical evidence base consists of over 100 animal studies, predominantly conducted at the University of Zagreb. A small pilot study in ulcerative colitis (4 patients) has been reported but was uncontrolled. No established human dosing, safety profile, or efficacy data from rigorous clinical trials exist. Products available through unregulated channels are not subject to pharmaceutical manufacturing standards, and their composition, purity, and sterility cannot be assured. The gap between the extensive animal literature and the near-complete absence of human clinical data is the defining feature of this compound's evidence base.